Consensus Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
422.8 ^USD	+0.90%		+5.41%	+3.91%

May. 10	Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	MT
May. 07	FOMO is Back

Evolution of the average Target Price on Vertex Pharmaceuticals Incorporated

Price target over the last 5 years

History of analyst recommendation changes

1930c5.xcFVKhGTUBuyYw2cp0B8SWrYahrGFgZQ502AxxDUpXA.v4snRn_6Ek_jCjjx0zEPPSHuCFWgdFAYkSf2imCV-l2dgxtyQL5kcYs0TA~c52d45e51dd6cb67d877a109a8acdf77

Analyst Recommendations on Vertex Pharmaceuticals Incorporated

ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins...	May. 07
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511	May. 07	MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430	May. 07	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating	May. 07	MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating	May. 07	MT
RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating	May. 07	MT
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating	May. 07	MT
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating	May. 07	MT
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515	Apr. 25	MT
UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating	Apr. 17	MT
Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
HC Wainwright Raises Vertex Pharmaceuticals' Price Target to $462 From $457, Maintains Buy Rating	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT
Evercore ISI Upgrades Vertex Pharmaceuticals to Outperform From In Line	Apr. 11	MT
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal	Apr. 11	MT
RBC Trims Price Target on Vertex Pharmaceuticals to $417 From $420, Keeps Sector Perform Rating	Feb. 22	MT
Wolfe Research Initiates Vertex Pharmaceuticals With Outperform Rating, $515 Price Target	Feb. 15	MT
Fed officials fail to convince investors, who are focused on earnings	Feb. 07
ANALYST RECOMMENDATIONS : Caterpillar, Eli Lilly, Intel, Meta, T-Mobile...	Feb. 07
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $430 From $373, Keeps Hold Rating	Feb. 06	MT
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $511 From $485, Keeps Outperform Rating	Feb. 06	MT
Goldman Sachs Adjusts Vertex Pharmaceuticals' Price Target to $578 From $559, Keeps Buy Rating	Feb. 06	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $540 From $500, Maintains Overweight Rating	Feb. 06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

422.8 USD

Average target price

462.1 USD

Spread / Average Target

+9.30%

High Price Target

577 USD

Spread / Highest target

+36.48%

Low Price Target

325 USD

Spread / Lowest Target

-23.13%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vertex Pharmaceuticals Incorporated

Leerink Partners
Stifel Nicolaus
Piper Sandler
Morgan Stanley
RBC Capital Markets
Goldman Sachs
Bernstein
Wolfe Research
UBS
Guggenheim
HC Wainwright
Evercore ISI
Wells Fargo Securities
JPMorgan Chase
Barclays
Jefferies & Co.
Maxim
Oppenheimer
BofA Securities
Cantor Fitzgerald
Canaccord Genuity
BMO Capital
TD Cowen
Truist Securities
Baird
SVB Securities LLC
Argus
Cowen
SVB Leerink
Raymond James
Citigroup
Daiwa Securities
Credit Suisse

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar